Perspective on the development of new agents in thoracic cancers

Research output: Contribution to journalArticle

Abstract

The development of several targeted agents that play a critical role in the growth and survival of carcinomas has paved the way for a new era in the treatment of patients with thoracic malignancies. The novel antimetabolite pemetrexed has emerged as a key agent in the treatment of advanced malignant pleural mesothelioma (MPM). Inhibitors of the epidermal growth factor receptor (EGFR) are one of many promising targeted therapies for non-small-cell lung cancer (NSCLC). By utilizing agents that specifically target the biochemical and molecular changes underlying cancer, it is possible to envision a future in which combinations of therapies treat cancer on multiple fronts, significantly enhancing tumor responses and improving survival beyond current expectations.

Original languageEnglish
JournalLung Cancer
Volume50
Issue numberSUPPL. 1
DOIs
StatePublished - 2005

Fingerprint

Thorax
Pemetrexed
Neoplasms
Antimetabolites
Survival
Therapeutics
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Carcinoma
Growth

Keywords

  • Antimetabolite
  • Lung cancer
  • Malignant pleural mesothelioma
  • Non-small-cell lung cancer
  • Pemetrexed
  • Thoracic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Perspective on the development of new agents in thoracic cancers. / Einhorn, Lawrence.

In: Lung Cancer, Vol. 50, No. SUPPL. 1, 2005.

Research output: Contribution to journalArticle

@article{0cd20f0886c0418585d1be208b4d681d,
title = "Perspective on the development of new agents in thoracic cancers",
abstract = "The development of several targeted agents that play a critical role in the growth and survival of carcinomas has paved the way for a new era in the treatment of patients with thoracic malignancies. The novel antimetabolite pemetrexed has emerged as a key agent in the treatment of advanced malignant pleural mesothelioma (MPM). Inhibitors of the epidermal growth factor receptor (EGFR) are one of many promising targeted therapies for non-small-cell lung cancer (NSCLC). By utilizing agents that specifically target the biochemical and molecular changes underlying cancer, it is possible to envision a future in which combinations of therapies treat cancer on multiple fronts, significantly enhancing tumor responses and improving survival beyond current expectations.",
keywords = "Antimetabolite, Lung cancer, Malignant pleural mesothelioma, Non-small-cell lung cancer, Pemetrexed, Thoracic cancer",
author = "Lawrence Einhorn",
year = "2005",
doi = "10.1016/S0169-5002(05)81559-4",
language = "English",
volume = "50",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Perspective on the development of new agents in thoracic cancers

AU - Einhorn, Lawrence

PY - 2005

Y1 - 2005

N2 - The development of several targeted agents that play a critical role in the growth and survival of carcinomas has paved the way for a new era in the treatment of patients with thoracic malignancies. The novel antimetabolite pemetrexed has emerged as a key agent in the treatment of advanced malignant pleural mesothelioma (MPM). Inhibitors of the epidermal growth factor receptor (EGFR) are one of many promising targeted therapies for non-small-cell lung cancer (NSCLC). By utilizing agents that specifically target the biochemical and molecular changes underlying cancer, it is possible to envision a future in which combinations of therapies treat cancer on multiple fronts, significantly enhancing tumor responses and improving survival beyond current expectations.

AB - The development of several targeted agents that play a critical role in the growth and survival of carcinomas has paved the way for a new era in the treatment of patients with thoracic malignancies. The novel antimetabolite pemetrexed has emerged as a key agent in the treatment of advanced malignant pleural mesothelioma (MPM). Inhibitors of the epidermal growth factor receptor (EGFR) are one of many promising targeted therapies for non-small-cell lung cancer (NSCLC). By utilizing agents that specifically target the biochemical and molecular changes underlying cancer, it is possible to envision a future in which combinations of therapies treat cancer on multiple fronts, significantly enhancing tumor responses and improving survival beyond current expectations.

KW - Antimetabolite

KW - Lung cancer

KW - Malignant pleural mesothelioma

KW - Non-small-cell lung cancer

KW - Pemetrexed

KW - Thoracic cancer

UR - http://www.scopus.com/inward/record.url?scp=27744444563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744444563&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(05)81559-4

DO - 10.1016/S0169-5002(05)81559-4

M3 - Article

C2 - 16291431

AN - SCOPUS:27744444563

VL - 50

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 1

ER -